Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia

References

• Heisterkamp N, Groffen J. BCR/ABL gene structure and BCR function. In: Carella A, Daley G, Eaves C, Goldman J, Hehlman R, eds. Chronic myeloid leukemia: Biology and treatment, 2001:3-17.
   Google Scholar
• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5:172 - 83; http://dx.doi.org/10.1038/nrc1567; PMID: 15719031
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Pfeifer H. First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol 2009; 21:Suppl 1 S43 - 6; http://dx.doi.org/10.1097/01.cco.0000357476.43164.6b; PMID: 19561414
   PubMedGoogle Scholar
• Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol 2009; 27:5175 - 81; http://dx.doi.org/10.1200/JCO.2008.21.2514; PMID: 19805687
   PubMed Web of Science ®Google Scholar
• Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 2005; 131:579 - 87; http://dx.doi.org/10.1111/j.1365-2141.2005.05773.x; PMID: 16351633
   PubMed Web of Science ®Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354:166 - 78; http://dx.doi.org/10.1056/NEJMra052603; PMID: 16407512
   PubMed Web of Science ®Google Scholar
• Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10:125 - 34; http://dx.doi.org/10.1016/S1470-2045(08)70339-5; PMID: 19138562
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542 - 51; http://dx.doi.org/10.1056/NEJMoa055104; PMID: 16775235
   PubMed Web of Science ®Google Scholar
• Jones D, Thomas D, Yin CC, O’Brien S, Cortes JE, Jabbour E, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008; 113:985 - 94; http://dx.doi.org/10.1002/cncr.23666; PMID: 18615627
   PubMed Web of Science ®Google Scholar
• Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009; 16:232 - 45; http://dx.doi.org/10.1016/j.ccr.2009.07.030; PMID: 19732723
   PubMed Web of Science ®Google Scholar
• Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009; 9:665 - 74; http://dx.doi.org/10.1038/nrc2714; PMID: 19693095
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990; 344:251 - 3; http://dx.doi.org/10.1038/344251a0; PMID: 2179728
   PubMed Web of Science ®Google Scholar
• Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V, et al. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer 2007; 6:67; http://dx.doi.org/10.1186/1476-4598-6-67; PMID: 17958915
   PubMed Web of Science ®Google Scholar
• Mishra S, Pertz V, Zhang B, Kaur P, Shimada H, Groffen J, et al. Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2. Leukemia 2007; •••:178 - 80
   PubMed Web of Science ®Google Scholar
• Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res 2006; 66:5387 - 93; http://dx.doi.org/10.1158/0008-5472.CAN-05-3058; PMID: 16707466
   PubMed Web of Science ®Google Scholar
• Zhang B, Groffen J, Heisterkamp N. Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. . Leukemia 2007; 21:1189 - 97; http://dx.doi.org/10.1038/sj.leu.2404667
   PubMed Web of Science ®Google Scholar
• Zhang B, Groffen J, Heisterkamp N. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood 2005; 106:1355 - 61; http://dx.doi.org/10.1182/blood-2004-09-3655; PMID: 15860663
   PubMed Web of Science ®Google Scholar
• O’Hare T, Walters DK, Deininger MW, Druker BJ. AMN107: tightening the grip of imatinib. Cancer Cell 2005; 7:117 - 9; http://dx.doi.org/10.1016/j.ccr.2005.01.020; PMID: 15710324
   PubMed Web of Science ®Google Scholar
• Morgillo F, Lee HY. Lonafarnib in cancer therapy. Expert Opin Investig Drugs 2006; 15:709 - 19; http://dx.doi.org/10.1517/13543784.15.6.709; PMID: 16732721
   PubMed Web of Science ®Google Scholar
• Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, et al. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med 2009; 206:1739 - 53; http://dx.doi.org/10.1084/jem.20090004; PMID: 19620627
   PubMed Web of Science ®Google Scholar
• Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108:785 - 91; PMID: 11560944
   PubMed Web of Science ®Google Scholar
• Lee KH, Ono M, Inui M, Yuasa T, Takai T. Stimulatory function of gp49A, a murine Ig-like receptor, in rat basophilic leukemia cells. J Immunol 2000; 165:4970 - 7; PMID: 11046024
   PubMed Web of Science ®Google Scholar
• Chang CC, Liu Z, Vlad G, Qin H, Qiao X, Mancini DM, et al. Ig-like transcript 3 regulates expression of proinflammatory cytokines and migration of activated T cells. J Immunol 2009; 182:5208 - 16; http://dx.doi.org/10.4049/jimmunol.0804048; PMID: 19380766
   PubMed Web of Science ®Google Scholar
• Gu X, Laouar A, Wan J, Daheshia M, Lieberman J, Yokoyama WM, et al. The gp49B1 inhibitory receptor regulates the IFN-gamma responses of T cells and NK cells. J Immunol 2003; 170:4095 - 101; PMID: 12682239
   PubMed Web of Science ®Google Scholar
• Katz HR. Inhibition of pathologic inflammation by leukocyte Ig-like receptor B4 and related inhibitory receptors. Immunol Rev 2007; 217:222 - 30; http://dx.doi.org/10.1111/j.1600-065X.2007.00522.x; PMID: 17498062
   PubMed Web of Science ®Google Scholar
• Pahl MV, Vaziri ND, Yuan J, Adler SG. Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease. Clin J Am Soc Nephrol 2010; 5:56 - 61; http://dx.doi.org/10.2215/CJN.03390509; PMID: 19833906
   PubMed Web of Science ®Google Scholar
• Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA. Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol 2007; 178:6557 - 66; PMID: 17475886
   PubMed Web of Science ®Google Scholar
• Kuan CT, Wakiya K, Dowell JM, Herndon JE 2nd, Reardon DA, Graner MW, et al. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 2006; 12:1970 - 82; http://dx.doi.org/10.1158/1078-0432.CCR-05-2797; PMID: 16609006
   PubMed Web of Science ®Google Scholar
• Arce I, Martínez-Muñoz L, Roda-Navarro P, Fernández-Ruiz E. The human C-type lectin CLECSF8 is a novel monocyte/macrophage endocytic receptor. Eur J Immunol 2004; 34:210 - 20; http://dx.doi.org/10.1002/eji.200324230; PMID: 14971047
   PubMed Web of Science ®Google Scholar
• Graham LM, Brown GD. The Dectin-2 family of C-type lectins in immunity and homeostasis. Cytokine 2009; 48:148 - 55; http://dx.doi.org/10.1016/j.cyto.2009.07.010; PMID: 19665392
   PubMed Web of Science ®Google Scholar
• Porcheray F, Viaud S, Rimaniol AC, Léone C, Samah B, Dereuddre-Bosquet N, et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005; 142:481 - 9; PMID: 16297160
   PubMed Web of Science ®Google Scholar
• Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009; 69:4001 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-4173; PMID: 19383907
   PubMed Web of Science ®Google Scholar
• Terpos E, Politou M, Viniou N, Rahemtulla A. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma 2005; 46:1699 - 707; http://dx.doi.org/10.1080/10428190500175049; PMID: 16263571
   PubMed Web of Science ®Google Scholar
• Coelho AL, Schaller MA, Benjamim CF, Orlofsky AZ, Hogaboam CM, Kunkel SL. The chemokine CCL6 promotes innate immunity via immune cell activation and recruitment. J Immunol 2007; 179:5474 - 82; PMID: 17911634
   PubMed Web of Science ®Google Scholar
• Dolgachev V, Thomas M, Berlin A, Lukacs NW. Stem cell factor-mediated activation pathways promote murine eosinophil CCL6 production and survival. J Leukoc Biol 2007; 81:1111 - 9; http://dx.doi.org/10.1189/jlb.0906595; PMID: 17234680
   PubMed Web of Science ®Google Scholar
• Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350:1828 - 37; http://dx.doi.org/10.1056/NEJMoa032520; PMID: 15115829
   PubMed Web of Science ®Google Scholar
• Dean RA, Cox JH, Bellac CL, Doucet A, Starr AE, Overall CM. Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood 2008; 112:3455 - 64; http://dx.doi.org/10.1182/blood-2007-12-129080; PMID: 18660381
   PubMed Web of Science ®Google Scholar
• Kassim SY, Fu X, Liles WC, Shapiro SD, Parks WC, Heinecke JW. NADPH oxidase restrains the matrix metalloproteinase activity of macrophages. J Biol Chem 2005; 280:30201 - 5; http://dx.doi.org/10.1074/jbc.M503292200; PMID: 15983040
   PubMed Web of Science ®Google Scholar
• Meng QR, Gideon KM, Harbo SJ, Renne RA, Lee MK, Brys AM, et al. Gene expression profiling in lung tissues from mice exposed to cigarette smoke, lipopolysaccharide, or smoke plus lipopolysaccharide by inhalation. Inhal Toxicol 2006; 18:555 - 68; http://dx.doi.org/10.1080/08958370600686226; PMID: 16717027
   PubMed Web of Science ®Google Scholar
• Hofmann HS, Hansen G, Richter G, Taege C, Simm A, Silber RE, et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin Cancer Res 2005; 11:1086 - 92; PMID: 15709175
   PubMed Web of Science ®Google Scholar
• Sarkar S, Nuttall RK, Liu S, Edwards DR, Yong VW. Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res 2006; 66:11771 - 80; http://dx.doi.org/10.1158/0008-5472.CAN-05-0470; PMID: 17178873
   PubMed Web of Science ®Google Scholar
• Sato K, Shikano S, Xia G, Takao J, Chung JS, Cruz PD Jr., et al. Selective expression of vacuolar H+-ATPase subunit d2 by particular subsets of dendritic cells among leukocytes. Mol Immunol 2006; 43:1443 - 53; http://dx.doi.org/10.1016/j.molimm.2005.07.035; PMID: 16144709
   PubMed Web of Science ®Google Scholar
• Karlstetter M, Walczak Y, Weigelt K, Ebert S, Van den Brulle J, Schwer H, et al. The novel activated microglia/macrophage WAP domain protein, AMWAP, acts as a counter-regulator of proinflammatory response. J Immunol 2010; 185:3379 - 90; http://dx.doi.org/10.4049/jimmunol.0903300; PMID: 20709948
   PubMed Web of Science ®Google Scholar
• Paul WE. Fundamental immunology. Philadelphia: Lippincott Williams & Wilkins, 2003.
   Google Scholar
• Rajakariar R, Hilliard M, Lawrence T, Trivedi S, Colville-Nash P, Bellingan G, et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci U S A 2007; 104:20979 - 84; http://dx.doi.org/10.1073/pnas.0707394104; PMID: 18077391
   PubMed Web of Science ®Google Scholar
• Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11:155 - 61; http://dx.doi.org/10.1038/ni.1836; PMID: 20037584
   PubMed Web of Science ®Google Scholar
• Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol 1996; 156:1 - 4; PMID: 8598448
   PubMed Web of Science ®Google Scholar
• Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6:480 - 98; http://dx.doi.org/10.1038/nrd2308; PMID: 17541420
   PubMed Web of Science ®Google Scholar
• Poyer F, Coquerel B, Pegahi R, Cazin L, Norris V, Vannier JP, et al. Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia. Leuk Res 2009; 33:407 - 17; http://dx.doi.org/10.1016/j.leukres.2008.08.019; PMID: 18829111
   PubMed Web of Science ®Google Scholar
• Pegahi R, Poyer F, Legrand E, Cazin L, Vannier JP, Lamacz M. Spontaneous and cytokine-evoked production of matrix metalloproteinases by bone marrow and peripheral blood pre-B cells in childhood acute lymphoblastic leukaemia. Eur Cytokine Netw 2005; 16:223 - 32; PMID: 16266864
   PubMed Web of Science ®Google Scholar
• Schneider P, Costa O, Legrand E, Bigot D, Lecleire S, Grassi V, et al. In vitro secretion of matrix metalloprotease 9 is a prognostic marker in childhood acute lymphoblastic leukemia. Leuk Res 2010; 34:24 - 31; http://dx.doi.org/10.1016/j.leukres.2009.07.039; PMID: 19748669
   PubMed Web of Science ®Google Scholar
• Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, et al. A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006; 10:425 - 35; http://dx.doi.org/10.1016/j.ccr.2006.09.014; PMID: 17097564
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860 - 7; http://dx.doi.org/10.1038/nature01322; PMID: 12490959
   PubMed Web of Science ®Google Scholar
• Robak P, Smolewski P, Robak T. The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. Leuk Lymphoma 2008; 49:1452 - 62; http://dx.doi.org/10.1080/10428190802108854; PMID: 18608871
   PubMed Web of Science ®Google Scholar
• Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A, et al. Cellular and molecular pathways linking inflammation and cancer. Immunobiology 2009; 214:761 - 77; http://dx.doi.org/10.1016/j.imbio.2009.06.014; PMID: 19616341
   PubMed Web of Science ®Google Scholar
• Kovalchuk AL, Kim JS, Park SS, Coleman AE, Ward JM, Morse HC 3rd, et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A 2002; 99:1509 - 14; http://dx.doi.org/10.1073/pnas.022643999; PMID: 11805288
   PubMed Web of Science ®Google Scholar
• Ramiro AR, Jankovic M, Callen E, Difilippantonio S, Chen HT, McBride KM, et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 2006; 440:105 - 9; http://dx.doi.org/10.1038/nature04495; PMID: 16400328
   PubMed Web of Science ®Google Scholar
• Nelson D, Ganss R. Tumor growth or regression: powered by inflammation. J Leukoc Biol 2006; 80:685 - 90; http://dx.doi.org/10.1189/jlb.1105646; PMID: 16864602
   PubMed Web of Science ®Google Scholar
• Cheok MH, Yang W, Pui CH, Downing JR, Cheng C, Naeve CW, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 2003; 34:85 - 90; http://dx.doi.org/10.1038/ng1151; PMID: 12704389
   PubMed Web of Science ®Google Scholar
• Rhein P, Scheid S, Ratei R, Hagemeier C, Seeger K, Kirschner-Schwabe R, et al. Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia. . Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2007; 21:897 - 905
   PubMed Web of Science ®Google Scholar
• Rhein P, Mitlohner R, Basso G, Gaipa G, Dworzak MN, Kirschner-Schwabe R, et al. CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. Blood 2010; 115:3763 - 71; http://dx.doi.org/10.1182/blood-2009-10-247585; PMID: 20228269
   PubMed Web of Science ®Google Scholar
• Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L, et al. Inflammation and IGF-I activate the Akt pathway in breast cancer. International journal of cancer Journal international du cancer 2007; 120:796-805.
   Google Scholar
• Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs 2009; 18:1893 - 905; http://dx.doi.org/10.1517/13543780903321490; PMID: 19852565
   PubMed Web of Science ®Google Scholar
• Ringshausen I, Dechow T, Schneller F, Weick K, Oelsner M, Peschel C, et al. Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. . Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2004; 18:1964 - 70; http://dx.doi.org/10.1038/sj.leu.2403544
   PubMed Web of Science ®Google Scholar
• Gaundar SS, Bradstock KF, Bendall LJ. p38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells. Cell Cycle 2009; 8:2975 - 83; http://dx.doi.org/10.4161/cc.8.18.9545; PMID: 19713744
   PubMed Web of Science ®Google Scholar
• Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem 2001; 276:28570 - 7; http://dx.doi.org/10.1074/jbc.M011685200; PMID: 11353767
   PubMed Web of Science ®Google Scholar
• Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 2004; 279:25345 - 52; http://dx.doi.org/10.1074/jbc.M400590200; PMID: 15056660
   PubMed Web of Science ®Google Scholar
• Dumka D, Puri P, Carayol N, Lumby C, Balachandran H, Schuster K, et al. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma 2009; 50:2017 - 29; http://dx.doi.org/10.3109/10428190903147637; PMID: 19672773
   PubMed Web of Science ®Google Scholar
• Fei F, Stoddart S, Muschen M, Kim YM, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. . Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2010; 24:813 - 20; http://dx.doi.org/10.1038/leu.2009.302
   PubMed Web of Science ®Google Scholar
• Hawkes SP, Li H, Taniguchi GT. Zymography and reverse zymography for detecting MMPs, and TIMPs. Methods Mol Biol 2001; 151:399 - 410; PMID: 11217315
   PubMedGoogle Scholar
• Behan JW, Yun JP, Proektor MP, Ehsanipour EA, Arutyunyan A, Moses AS, et al. Adipocytes impair leukemia treatment in mice. Cancer Res 2009; 69:7867 - 74; http://dx.doi.org/10.1158/0008-5472.CAN-09-0800; PMID: 19773440
   PubMed Web of Science ®Google Scholar